An interventional study of an integrated multimodal lifestyle intervention (MLifeI) in Schizophrenia, sponsored by I-Shou University. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-04-15.
Sponsored by I-Shou University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 181 studies in Schizophrenia with a site in Taiwan — 23 open to participants now, 26 under way, none of them phase 3. Schizophrenia · Taiwan.
Among the 181 studies in Schizophrenia with a site in Taiwan, this one is the 100th largest by enrollment of the 153 interventional ones that give a count, is one of 7 that started in 2016, is one of 56 with no phase, and was the 144th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →23 of the 181 studies in Schizophrenia with a site in Taiwan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Taiwan, United States, Argentina and 4 more countries
Ages 18–55
China Medical University Hospital · Sites in Taiwan
Ages 20–65
Taipei Medical University Shuang Ho Hospital · Sites in Taiwan
Ages 20–70
China Medical University Hospital · Sites in Taiwan
Ages 18–65
National Taiwan University Hospital · Sites in Taiwan
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 20 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
181 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 35 · Phase 3 41 · Phase 4 24
First in 2000; this study’s year is marked. 7 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Median enrollment 85 across the 153 interventional studies, 110 across the 26 observational. Of the 129 that completed or were terminated, 34 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 181 have an industry lead sponsor. The 10 most frequent:
I-Shou University is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
I-Shou University has 2 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
11 of the studies in Schizophrenia with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04917302China Medical University HospitalCombination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia | 2026-11 |
| NCT06563752National Yang Ming Chiao Tung UniversityExploring the Effectiveness of Digital Anti-stigma Therapy on Illness Perception and Perceived Stigma in Patients With Schizophrenia and Their Primary Caregivers | 2026-12 |
| NCT04959201China Medical University HospitalCombination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia | 2026-12 |
| NCT07781007Kaohsiung Kai-Suan Psychiatric HospitalEffectiveness of a Board Game Intervention on Cognitive and Functional Outcomes in Older Adults With Schizophrenia | 2026-12-02 |
| NCT05830903National Taiwan University HospitalDevelop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 181 studies in Schizophrenia with a site in Taiwan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Total cholesterol levels and other lipids are associated with violence in psychiatric patients. There is a paucity of studies on preventive interventions. In this study, an integrated multimodal lifestyle intervention (MLifeI) for management of repetitive violence in schizophrenia is proposed. A controlled clinical trial was carried out to evaluate the effects of MLifeI on management of repetitive violence through regulation of serum lipids, TC in particular, to the recommended levels in schizophrenia. The investigators examined whether the MLifeI could: 1. regulate or balance lipid profiles; 2. reduce violence risk; 3. improve impulsivity; and 4. improve general cognitive functioning.
Total cholesterol levels and other lipids are associated with violence in psychiatric patients. There is a paucity of studies on preventive interventions. In this study, an integrated multimodal lifestyle intervention (MLifeI) for management of repetitive violence in schizophrenia is proposed. A controlled clinical trial was carried out to evaluate the effects of MLifeI on management of repetitive violence through regulation of serum lipids, TC in particular, to the recommended levels in schizophrenia. The investigators examined whether the MLifeI could: 1. regulate or balance lipid profiles; 2. reduce violence risk; 3. improve impulsivity; and 4. improve general cognitive functioning. The multimodal lifestyle intervention included psychoeducation, lifestyle modification and health promotion and exercise. Outcome measures comprised lipid profiles, body mass index and violence-related parameters.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The MLifeI program focused on the roles of health responsibility, review of lipid profile, complications of imbalanced lipid profile, lipid management and nutritional education.
Other: an integrated multimodal lifestyle intervention (MLifeI)
The control group is the Treatment as Usual (TAU).
The MLifeI program focused on the roles of health responsibility, review of lipid profile, complications of imbalanced lipid profile, lipid management and nutritional education.
Weight in kilograms
Clinical Assessment: weight.
Time frame: Change of weight from baseline and 6 months (3-month follow-up)
Height in meters
Clinical Assessment: height.
Time frame: Change of weight from baseline and 6 months (3-month follow-up)
Body Mass Index (BMI)
Clinical Assessment: Body Mass Index; Weight and height will be combined to report BMI in kg/m\^2. The World Health Organisation defines an adult who has a BMI between 25 and 29.9 as overweight - an adult who has a BMI of 30 or higher is considered obese - a BMI below 18.5 is considered underweight, and between 18.5 to 24.9 a healthy weight.
Time frame: Change of weight from baseline and 6 months (3-month follow-up)
Routine test in the ward of total cholesterol, triglyceride, low-density lipoprotein and high-density lipoprotein (Change is being assessed, mg/dL)
Lipid profiles. Assessment of serum metabolites.
Time frame: Change of violence risk from baseline (T1) and 6 months (T3, 3-month follow-up)
Violence Risk Screening (Change is being assessed)
Questionnaires of violence. A higher score indicates a higher violence risk.
Time frame: Change of violence risk from baseline (T1), 3 months (T2, end of treatment), and 6 months (T3, 3-month follow-up)
Attribution Questionnaire (Change is being assessed)
Questionnaires of violence attributions. The Attribution Questionnair was applied to measure the participant's internal/external attributions about the causality and likelihood of violence and responsibility for changing the behavior. The measure was rated on a continuum scale from 1 (e.g., not at all likely; not at all able, etc.) to 7 (e.g., totally due to me; totally likely; totally able, etc.).
Time frame: Change of violence risk from baseline (T1), 3 months (T2, end of treatment), and 6 months (T3, 3-month follow-up)
Modified Overt Aggression Scale (Change is being assessed)
Questionnaires of aggression frequency.
Time frame: Change of violence risk from baseline (T1), 3 months (T2, end of treatment), and 6 months (T3, 3-month follow-up)
Buss-Perry Aggression Questionnaire (Change is being assessed)
Questionnaires of violence/aggression. The higher the score is, the higher the participant has the violent behavior.
Time frame: Change of violence risk from baseline (T1), 3 months (T2, end of treatment), and 6 months (T3, 3-month follow-up)
Barratt Impulsiveness Scale (Change is being assessed)
Questionnaires of impulsivity. The score ranged from 1 (rarely/never) to 4 (almost always/always). The higher the scores indicates the greater the impulsivity.
Time frame: Change of violence risk from baseline (T1), 3 months (T2, end of treatment), and 6 months (T3, 3-month follow-up)
Mini-Mental State Examination (Change is being assessed)
Questionnaires of cognitive functioning. The MMSE ranged from 0 to 30, where higher scores indicate better cognitive functioning.
Time frame: Change of violence risk from baseline (T1), 3 months (T2, end of treatment), and 6 months (T3, 3-month follow-up)
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2016 to primary completion in Aug 2018, 23 months.
Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 23 months is below that.
Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
I-Shou University